KRAS

REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted…

Codon-specific KRAS mutations are predictive of an overall survival (OS) benefit for…

<!-- Name:DistributionId Value:8752878 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.Biomea Fusion will now initiate a Phase I/Ib…

PARIS -- Targeted therapy in previously treated non-small cell lung cancer (NSCLC) patients harboring KRAS G12C mutations…

The incident will also be reported to the Indian Computer Emergency Response team in accordance with the guidelines issued by CERT-In from time to time, according to a circular. The…

Capital markets regulator SEBI has asked the KYC Registration Agencies (KRAs) to report all cyber attacks, threats and breaches experienced by them within six hours of detecting such…

CHICAGO -- More than 40% of patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) responded to treatment with…

CHICAGO -- Adding an EGFR inhibitor to chemotherapy significantly improved overall survival (OS) in advanced KRAS wild-type…

Capital markets regulator SEBI on Monday changed the cybersecurity and the cyber resilience framework of KYC Registration Agencies (KRAs) and mandated them to conduct a comprehensive cyber…